E-LIB Suche - Ergebnisse für: Manda, Sudhir

1

A phase 3b study of venetoclax and azacitidine or decitabin..:

Manda, Sudhir ; Anz III, Bertrand M. ; Benton, Christopher...
Hematological Oncology. 42 (2024) 3 - p. , 2024

Link: https://doi.org/10.1002/..

2

Genomic landscape of patients in a phase II study of zanubr..:

Xu, Linlin ; Shadman, Mazyar ; Flinn, Ian W....
Haematologica. , 2024

Link: https://doi.org/10.3324/..

3

In-class transition (iCT) of proteasome inhibitor-based the..:

Rifkin, Robert M. ; Girnius, Saulius K. ; Noga, Stephen J....
Blood Cancer Journal. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

4

PB2089: IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO O..:

Girnius, Saulius K. ; Richter, Joshua ; Lyons, Roger M....
HemaSphere. 7 (2023) S3 - p. e149880d , 2023

Link: https://doi.org/10.1097/..

5

P-114 In-class transition (iCT) from parenteral bortezomib ..:

Girnius, Saulius ; Richter, Joshua ; Lyons, Roger...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S97-S98 , 2023

Link: https://doi.org/10.1016/..

6

POSTER: MM-465 In-Class Transition (iCT) from Parenteral Bo..:

Girnius, Saulius K. ; Richter, Joshua ; Lyons, Roger...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S221 , 2023

Link: https://doi.org/10.1016/..

7

MM-465 In-Class Transition (iCT) from Parenteral Bortezomib..:

Girnius, Saulius K. ; Richter, Joshua ; Lyons, Roger...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S501 , 2023

Link: https://doi.org/10.1016/..

8

Poster: MM-253 Efficacy, Safety, and Quality of Life (QoL) ..:

Manda, Sudhir ; Yimer, Habte A. ; Birhiray, Ruemu E....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S179 , 2022

Link: https://doi.org/10.1016/..

9

MM-253 Efficacy, Safety, and Quality of Life (QoL) in Patie..:

Manda, Sudhir ; Yimer, Habte A. ; Birhiray, Ruemu E....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S416-S417 , 2022

Link: https://doi.org/10.1016/..

10

P-204: In-class transition (iCT) from parenteral bortezomib..:

Yimer, Habte ; Birhiray, Ruemu ; Boccia, Ralph...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S147-S148 , 2022

Link: https://doi.org/10.1016/..

11

CLL-076: Phase 3b Study to Evaluate Debulking Regimens Prio..:

Sharman, Jeff ; Andorsky, David ; Melear, Jason...
Clinical Lymphoma Myeloma and Leukemia. 20 (2020) - p. S219-S220 , 2020

Link: https://doi.org/10.1016/..

12

Feasibility of Long-term Proteasome Inhibition in Multiple ..:

Manda, Sudhir ; Yimer, Habte A. ; Noga, Stephen J....
Clinical Lymphoma Myeloma and Leukemia. 20 (2020) 11 - p. e910-e925 , 2020

Link: https://doi.org/10.1016/..

13

MM-202: Long-Term Proteasome Inhibition in Multiple Myeloma..:

Birhiray, Ruemu E. ; Manda, Sudhir ; Girnius, Saulius K....
Clinical Lymphoma Myeloma and Leukemia. 20 (2020) - p. S299 , 2020

Link: https://doi.org/10.1016/..

14

Long-term proteasome inhibition in newly diagnosed multiple..:

Yimer, Habte ; Rifkin, Robert ; Noga, Stephen...
Clinical Lymphoma Myeloma and Leukemia. 19 (2019) 10 - p. e11 , 2019

Link: https://doi.org/10.1016/..

15

Comorbidities predict inferior outcomes in chronic lymphocy..:

Gordon, Max J. ; Churnetski, Michael ; Alqahtani, Hamood...
Cancer. 124 (2018) 15 - p. 3192-3200 , 2018

Link: https://doi.org/10.1002/..